Application of clinical judgment and guidelines to achieving glycemic goals in type 2 diabetes: Focus on pharmacologic therapy

Postgraduate Medicine

Volumn 126, Issue 3, 2014, Pages 95-106

  Yacoub, Tamer G ^a  

^a Prima CARE PC   (United States)

Author keywords

American Academy of Clinical Endocrinologists; American Diabetes Association; Antihyperglycemic drugs; Guidelines; Hemoglobin A1c goals; Type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BROMOCRIPTINE; BROMOCRIPTINE MESILATE; CANAGLIFLOZIN; COLESEVELAM; CYTOCHROME P450; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; MEGLITINIDE; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SITAGLIPTIN; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN;

ARTICLE; CLINICAL DECISION MAKING; CLINICAL TRIAL (TOPIC); DIET; EXERCISE; FUNGAL GENITAL INFECTION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; META ANALYSIS (TOPIC); MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; URINARY TRACT INFECTION; WEIGHT GAIN; BLOOD GLUCOSE MONITORING; BODY WEIGHT; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; DRUG INTERACTION; PATIENT CARE PLANNING; REVIEW;

BLOOD GLUCOSE SELF-MONITORING; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DIET; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; EXERCISE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; PATIENT CARE PLANNING; PRACTICE GUIDELINES AS TOPIC;

EID: 84906932774     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2014.05.2759     Document Type: Article

References (59)

1. Liday C. Overview of the guidelines and evidence for the pharmacologic management of type 2 diabetes mellitus. Pharmacotherapy. 2011;31(12 Suppl):37S-43S.
2. American Diabetes Assocation (ADA). Standards of medical care in diabetes-2014. Diabetes Care. 2014;37(Suppl 1):S14-S80.
3. Handelsman Y, Mechanick JI, Blonde L, et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract. 2011;17(Suppl 2):1-53.
4. Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE comprehensive diabetes management algorithm 2013. Endocr Pract. 2013;19(2):327-336.
5. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364-1379.
6. Bohannon NJ. Individualized treatment of type 2 diabetes mellitus using noninsulin agents: clinical considerations for the primary care physician. Postgrad Med. 2012;124(4):95-108.
7. Raz I, Riddle MC, Rosenstock J, et al. Personalized management of hyperglycemia in type 2 diabetes: reflections from a Diabetes Care Editors' Expert Forum. Diabetes Care. 2013;36(6):1779-1788.
8. Steinsbekk A, Rygg LO, Lisulo M, Rise MB, Fretheim A. Group based diabetes self-management education compared to routine treatment for people with type 2 diabetes mellitus. A systematic review with metaanalysis. BMC Health Serv Res. 2012;12:213.
9. Alexander GC, Sehgal NL, Moloney RM, Stafford RS. National trends in treatment of type 2 diabetes mellitus, 1994-2007. Arch Intern Med. 2008;168(19):2088-2094.
10. Verspohl EJ. Novel pharmacological approaches to the treatment of type 2 diabetes. Pharmacol Rev. 2012;64(2):188-237.
11. Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58(4):773-795.
12. Davidson JA, Blonde L, Jellinger PS, Lebovitz H, Parkin CG. Road map for the prevention and treatment of type 2 diabetes. Endocr Pract. 2006;12(Suppl 1):6-12.
13. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2006;29(8):1963-1972.
14. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15(6): 540-559.
15. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193-203.
16. Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn't. BMJ. 1996;312(7023):71-72.
17. Kung J, Miller RR, Mackowiak PA. Failure of clinical practice guidelines to meet institute of medicine standards: two more decades of little, if any, progress. Arch Intern Med. 2012;172(21):1628-1633.
18. Seidu S, Khunti K. Non-adherence to diabetes guidelines in primary care-the enemy of evidence-based practice. Diabetes Res Clin Pract. 2012;95(3):301-302.
19. Vigersky RA. A review and critical analysis of professional societies' guidelines for pharmacologic management of type 2 diabetes mellitus. Curr Diab Rep. 2012;12(3):246-254.
20. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia. 2003;46(1):3-19.
21. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest. 1999;104(6):787-794.
22. Smith RJ, Nathan DM, Arslanian SA, et al. Individualizing therapies in type 2 diabetes mellitus based on patient characteristics: what we know and what we need to know. J Clin Endocrinol Metab. 2010;95(4):1566-1574.
23. Aschner PJ, Ruiz AJ. Metabolic memory for vascular disease in diabetes. Diabetes Technol Ther. 2012;14(Suppl 1):S68-S74.
24. Tsapas A, Matthews DR. N of 1 trials in diabetes: making individual therapeutic decisions. Diabetologia. 2008;51(6):921-925.
25. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355(23):2427-2443.
26. Qaseem A, Humphrey LL, Sweet DE, et al. Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2012;156(3):218-231.
27. Monnier L, Colette C. Fasting glucose and postprandial glycemia: which is the best target for improving outcomes? The Apollo and 4-T Trials. Expert Opin Pharmacother. 2008;9(16):2857-2865.
28. Pozzilli P, Leslie RD, Chan J, et al. The A1C and ABCD of glycaemia management in type 2 diabetes: a physician's personalized approach. Diabetes Metab Res Rev. 2010;26(4):239-244.
29. Freeman JS, Gross B. Potential drug interactions associated with treatments for type 2 diabetes and its comorbidities: a clinical pharmacology review. Expert Rev Clin Pharmacol. 2012;5(1):31-42.
30. Boussageon R, Supper I, Bejan-Angoulvant T, et al. Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials. PLoS Med. 2012;9(4):e1001204.
31. Chapell R, Gould AL, Alexander CM. Baseline differences in A1C explain apparent differences in efficacy of sitagliptin, rosiglitazone and pioglitazone. Diabetes Obes Metab. 2009;11(11):1009-1016.
32. Riddle MC, Vlajnic A, Zhou R, Rosenstock J. Baseline HbA1c predicts attainment of 7.0% HbA1c target with structured titration of insulin glargine in type 2 diabetes: a patient-level analysis of 12 studies. Diabetes Obes Metab. 2013;15(9):819-825.
33. DeFronzo RA, Stonehouse AH, Han J, Wintle ME. Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials. Diabet Med. 2010;27(3):309-317.
34. Riddle M, Umpierrez G, DiGenio A, Zhou R, Rosenstock J. Contributions of basal and postprandial hyperglycemia over a wide range of A1C levels before and after treatment intensification in type 2 diabetes. Diabetes Care. 2011;34(12):2508-2514.
35. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care. 2003;26(3):881-885.
36. Hurel SJ, Mohan V. Clinical decision making: managing postprandial hyperglycemia. J Assoc Physicians India. 2006;54:871-876.
37. Cornell S. Key considerations in pharmacotherapy for type 2 diabetes mellitus: a multiple target organ approach. J Clin Pharm Ther. 2012;37(3):254-259.
38. Schwartz SS. Optimizing glycemic control and minimizing the risk of hypoglycemia in patients with type 2 diabetes. Drugs in Context. 2013;2013:1-8.
39. Garber A, Henry RR, Ratner R, et al. Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes. Diabetes Obes Metab. 2011;13(4):348-356.
40. DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28(5):1092-1100.
41. Cornell S. Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes. J Clin Pharm Ther. 2012;37(5):510-524.
42. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132(6):2131-2157.
43. Vilsboll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes. 2001;50(3):609-613.
44. Handelsman Y. Role of bile acid sequestrants in the treatment of type 2 diabetes. Diabetes Care. 2011;34(Suppl 2):S244-S250.
45. Gaziano JM, Cincotta AH, Vinik A, et al. Effect of bromocriptine-QR (a quick-release formulation of bromocriptine mesylate) on major adverse cardiovascular events in type 2 diabetes subjects. J Am Heart Assoc. 2012;1(5):e002279.
46. Stenlof K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013;15(4):372-382.
47. Florez H, Scranton R, Farwell WR, et al. Randomized clinical trial assessing the efficacy and safety of bromocriptine-QR when added to ongoing thiazolidinedione therapy in patients with type 2 diabetes mellitus. J Diabetes Metab. 2011;2(7):1-8.
48. Zambrowicz B, Ding ZM, Ogbaa I, et al. Effects of LX4211, a dual SGLT1/ SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes. Clin Ther. 2013;35(3):273-285, e277.
49. Nadeau DA. Physiologic and weight-focused treatment strategies for managing type 2 diabetes mellitus: the metformin, glucagon-like peptide-1 receptor agonist, and insulin (MGI) approach. Postgrad Med. 2013;125(3):112-126.
50. Garber AJ. Treat-to-target trials: uses, interpretation and review of concepts. Diabetes Obes Metab. 2014;16(3):193-205.
51. Riddle MC, Rosenstock J, Gerich J; Insulin Glargine Study I. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26(11):3080-3086.
52. Riddle MC. Starting and advancing insulin for type 2 diabetes: algorithms and individualized methods are both necessary. J Clin Endocrinol Metab. 2008;93(2):372-374.
53. Rodbard HW, Jellinger PS. A critique of the 2012 ADA/EASD position statement. Diabetologia. 2012;55(10):2850-2852.
54. Matthews DR, Inzucchi SE, for the Position Statement Writing Group. ADA/EASD position statement of the treatment of type 2 diabetes: reply to Rodbard HW and Jellinger PS [letter], Scheen AJ [letter], and Ceriello A, Gallo M, Gentile S et al [letter]. Diabetologia. 2012;55(10):2856-2857.
55. Habib ZA, Tzogias L, Havstad SL, et al. Relationship between thiazolidinedione use and cardiovascular outcomes and all-cause mortality among patients with diabetes: a time-updated propensity analysis. Pharmacoepidemiol Drug Saf. 2009;18(6):437-447.
56. Cure P, Pileggi A, Alejandro R. Exenatide and rare adverse events. N Engl J Med. 2008;358(18):1969-1970, discussion 1971-1972.
57. Keche Y. Bromocriptine mesylate: Food and Drug Administration approved new approach in therapy of non-insulin dependant diabetes mellitus with poor glycemic control. J Pharm Bioallied Sci. 2010;2(2):148-150.
58. Montanya E, Sesti G. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus. Clin Ther. 2009;31(11):2472-2488.
59. Vlckova V, Cornelius V, Kasliwal R, Wilton L, Shakir SA. Hypoglycaemia with oral antidiabetic drugs: results from prescriptionevent monitoring cohorts of rosiglitazone, pioglitazone, nateglinide and repaglinide. Drug Saf. 2009;32(5):409-418.